Emergent BioSolutions anthrax vaccine gets boost - The Business Review (Albany):

http://lifeinafrica2.com/wordpress/history/
The Rockville-based company’s BioThrax has been granted a shelf life extension from the from its curreny three yearsto four. Under its contract with the Department of Healthb andHuman Services, the extension triggersa a milestone payment of $30 million for doses of the vaccine alreadgy delivered to the Strategic Nationall Stockpile. Emergent expects to recorsd that payment as revenuethis quarter. The shelf life extensionh also allows Emergent to charge more for futurwe doses of the vaccine deliveredr tothe government’s stockpile. That could raise the valuse of the contract to as muchas $405 millionj over the next several years.
Last the FDA approved a reducef vaccination schedule to five Emergent continues research that could lead to a further reductioh in the number ofdoses required, as well as the vaccine’s use to treaft patients after being exposed to Anthrax, not just as a pre-exposures vaccine. Emergent has supplied the government’e stockpile with 33 million doses of BioThracso far. It is contracted to continue adding to stockpileds throughlate 2011. BioThrax has been used to vaccinatw more than 2 million military personnel sincw the government first started buying the vaccinein 1998. Emergentt stock (NYSE: EBS) was up 90 centsd to $14.63 per share in afternoon trading.